• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于受控衰减参数值的诊断算法提高了慢性乙型肝炎患者肝硬度测量的准确性。

Controlled attenuation parameter value-based diagnostic algorithm improves the accuracy of liver stiffness measurement in chronic hepatitis B patients.

机构信息

Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang Liaoning Province, China.

Department of Health Management, Shengjing Hospital of China Medical University, Shenyang Liaoning Province, China.

出版信息

Aging (Albany NY). 2020 Aug 24;12(16):16072-16082. doi: 10.18632/aging.103522.

DOI:10.18632/aging.103522
PMID:32836216
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7485708/
Abstract

Liver stiffness measurement (LSM) frequently overestimates the severity of liver fibrosis because of steatosis. However, the impact of the controlled attenuation parameter (CAP) on liver stiffness cutoff values remains unknown; CAP was used to quantify and diagnose the severity of hepatic steatosis. The study was conducted to determine the effect of CAP on liver stiffness cutoff values in chronic hepatitis B (CHB) patients. A retrospective cross-sectional study was performed in liver biopsy-proven CHB patients. The median LSM (kPa) in the elevated CAP group was higher than that in the normal CAP group at the same fibrosis stage. For S2-4, the area under the receiver operating characteristic (AUROC) curve of LSM was 0.78 and 0.72 in the normal and elevated CAP groups, respectively. When a cutoff value of 8.9 kPa was used, the diagnostic accuracy was 77.82% and 63.41% in the normal and elevated CAP groups, respectively. Compared with the alanine transaminase (ALT)-based LSM algorithm, the CAP-based LSM algorithm had a similar correct diagnosis rate (33.64% vs. 33.94%, respectively) but a lower misdiagnosis rate (16.97% vs. 20.30%, respectively). The new CAP-based LSM diagnostic algorithm will improve the diagnostic accuracy of liver fibrosis in CHB patients.

摘要

肝脏硬度测量(LSM)常因脂肪变性而高估肝纤维化的严重程度。然而,受控衰减参数(CAP)对肝硬度截断值的影响尚不清楚;CAP 用于量化和诊断肝脂肪变性的严重程度。本研究旨在确定 CAP 对慢性乙型肝炎(CHB)患者肝硬度截断值的影响。对经肝活检证实的 CHB 患者进行了回顾性横断面研究。在相同纤维化分期时,CAP 值升高组的中位 LSM(kPa)高于 CAP 值正常组。对于 S2-4,LSM 的受试者工作特征(ROC)曲线下面积(AUROC)在 CAP 值正常和升高组分别为 0.78 和 0.72。当使用 8.9 kPa 的截断值时,CAP 值正常和升高组的诊断准确性分别为 77.82%和 63.41%。与基于丙氨酸氨基转移酶(ALT)的 LSM 算法相比,基于 CAP 的 LSM 算法的正确诊断率相似(分别为 33.64%和 33.94%),但误诊率较低(分别为 16.97%和 20.30%)。新的基于 CAP 的 LSM 诊断算法将提高 CHB 患者肝纤维化的诊断准确性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e12/7485708/f3487bf9eb17/aging-12-103522-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e12/7485708/c9fb6b68078a/aging-12-103522-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e12/7485708/30cf081af412/aging-12-103522-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e12/7485708/56c53d15ce95/aging-12-103522-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e12/7485708/f3487bf9eb17/aging-12-103522-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e12/7485708/c9fb6b68078a/aging-12-103522-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e12/7485708/30cf081af412/aging-12-103522-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e12/7485708/56c53d15ce95/aging-12-103522-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3e12/7485708/f3487bf9eb17/aging-12-103522-g004.jpg

相似文献

1
Controlled attenuation parameter value-based diagnostic algorithm improves the accuracy of liver stiffness measurement in chronic hepatitis B patients.基于受控衰减参数值的诊断算法提高了慢性乙型肝炎患者肝硬度测量的准确性。
Aging (Albany NY). 2020 Aug 24;12(16):16072-16082. doi: 10.18632/aging.103522.
2
Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis.中重度肝脂肪变可导致慢性乙型肝炎无显著纤维化患者肝硬度测量值偏高。
Aliment Pharmacol Ther. 2019 Jul;50(1):93-102. doi: 10.1111/apt.15298. Epub 2019 May 16.
3
How intrahepatic cholestasis affects liver stiffness in patients with chronic hepatitis B: a study of 1197 patients with liver biopsy.肝内胆汁淤积如何影响慢性乙型肝炎患者的肝硬度:一项 1197 例肝活检患者的研究。
Eur Radiol. 2020 Feb;30(2):1096-1104. doi: 10.1007/s00330-019-06451-x. Epub 2019 Oct 30.
4
Hepatic steatosis leads to overestimation of liver stiffness measurement in both chronic hepatitis B and metabolic-associated fatty liver disease patients.肝脂肪变性可导致慢性乙型肝炎和代谢相关脂肪性肝病患者的肝硬度测量值高估。
Clin Res Hepatol Gastroenterol. 2022 Oct;46(8):101957. doi: 10.1016/j.clinre.2022.101957. Epub 2022 May 21.
5
A diagnostic algorithm for assessment of liver fibrosis by liver stiffness measurement in patients with chronic hepatitis B.一种用于慢性乙型肝炎患者通过肝脏硬度测量评估肝纤维化的诊断算法。
J Viral Hepat. 2017 Nov;24(11):1005-1015. doi: 10.1111/jvh.12715. Epub 2017 May 12.
6
Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B.受控衰减参数对预测慢性乙型肝炎脂肪变性分级的诊断效能
Ann Hepatol. 2015 Nov-Dec;14(6):826-36. doi: 10.5604/16652681.1171762.
7
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.肝纤维化无创诊断技术评估非酒精性脂肪性肝病患者肝脏脂肪变及纤维化的准确性。
Gastroenterology. 2019 May;156(6):1717-1730. doi: 10.1053/j.gastro.2019.01.042. Epub 2019 Jan 25.
8
Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B.受控衰减参数对慢性乙型肝炎患者肝脂肪变性的诊断价值
World J Gastroenterol. 2014 Aug 14;20(30):10585-90. doi: 10.3748/wjg.v20.i30.10585.
9
A noninvasive indicator for the diagnosis of early hepatitis B virus-related liver fibrosis.一种用于诊断早期乙型肝炎病毒相关性肝纤维化的非侵入性指标。
Eur J Gastroenterol Hepatol. 2019 Feb;31(2):218-223. doi: 10.1097/MEG.0000000000001281.
10
Fibroscan can avoid liver biopsy in Indian patients with chronic hepatitis B.Fibroscan 可避免印度慢性乙型肝炎患者进行肝活检。
J Gastroenterol Hepatol. 2013 Nov;28(11):1738-45. doi: 10.1111/jgh.12318.

引用本文的文献

1
Impact of hepatic steatosis on treatment response of autoimmune hepatitis: A retrospective multicentre analysis.肝脂肪变性对自身免疫性肝炎治疗反应的影响:一项回顾性多中心分析。
Front Immunol. 2022 Dec 14;13:1040029. doi: 10.3389/fimmu.2022.1040029. eCollection 2022.

本文引用的文献

1
Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis.中重度肝脂肪变可导致慢性乙型肝炎无显著纤维化患者肝硬度测量值偏高。
Aliment Pharmacol Ther. 2019 Jul;50(1):93-102. doi: 10.1111/apt.15298. Epub 2019 May 16.
2
Non-invasive diagnosis and biomarkers in alcohol-related liver disease.酒精性肝病的无创诊断和生物标志物。
J Hepatol. 2019 Feb;70(2):273-283. doi: 10.1016/j.jhep.2018.11.025.
3
Chronic hepatitis B virus infection.慢性乙型肝炎病毒感染。
Lancet. 2018 Nov 24;392(10161):2313-2324. doi: 10.1016/S0140-6736(18)31865-8.
4
Access to Treatment for Hepatitis B Virus Infection - Worldwide, 2016.乙型肝炎病毒感染治疗的可及性 - 全球,2016 年。
MMWR Morb Mortal Wkly Rep. 2018 Jul 20;67(28):773-777. doi: 10.15585/mmwr.mm6728a2.
5
Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP).采用受控衰减参数(CAP)评估的慢性丙型肝炎(CHC)感染患者中中度/重度肝脂肪变性的患病率及预测因素
J Viral Hepat. 2018 Nov;25(11):1244-1250. doi: 10.1111/jvh.12930. Epub 2018 Jun 28.
6
Prognostic Value of Controlled Attenuation Parameter by Transient Elastography.瞬时弹性成像控制衰减参数的预后价值
Am J Gastroenterol. 2017 Dec;112(12):1812-1823. doi: 10.1038/ajg.2017.389. Epub 2017 Oct 31.
7
American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases.美国胃肠病学会协会弹性成像技术在慢性肝病中的作用技术评论。
Gastroenterology. 2017 May;152(6):1544-1577. doi: 10.1053/j.gastro.2017.03.016.
8
A diagnostic algorithm for assessment of liver fibrosis by liver stiffness measurement in patients with chronic hepatitis B.一种用于慢性乙型肝炎患者通过肝脏硬度测量评估肝纤维化的诊断算法。
J Viral Hepat. 2017 Nov;24(11):1005-1015. doi: 10.1111/jvh.12715. Epub 2017 May 12.
9
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.基于受控衰减参数(CAP)技术评估肝脂肪变的个体患者数据分析的荟萃分析。
J Hepatol. 2017 May;66(5):1022-1030. doi: 10.1016/j.jhep.2016.12.022. Epub 2016 Dec 28.
10
Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B.代谢综合征增加慢性乙型肝炎患者的心血管事件,但不增加肝脏事件和死亡。
Hepatology. 2016 Nov;64(5):1507-1517. doi: 10.1002/hep.28778. Epub 2016 Oct 1.